TMSxDCS: Pharmacologically augmenting transcranial magnetic stimulation for depression

Conditions

Major Depressive Disorder (MDD)

Brief summary

Percentage reduction from baseline MADRS score measured weekly for 6 weeks post-treatment

Detailed description

Percentage reduction from baseline MADRS-score at 6 months follow-up., Clinical remission (defined as a MADRS-score of ≤8) and clinical response (defined as a reduction from baseline MADRS score of >50%) at 6 weeks follow-up., Percentage reduction from baseline GAD-7-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Percentage reduction from baseline PHQ-9-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Change in performance on the cognitive test battery at 1 week follow-up., Side effect questionnaire taken immediately after treatment., EQ5D questionnaire taken at 6 weeks follow-up.

Related papers

No related papers found yet.

Interventions

DRUGDetermination of what placebo is adequate to ensure blinding will be done at a later stage(amendment)

DRUGas discussed in correspondence with the relevant METC.

DRUGCYCLOSERINE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Percentage reduction from baseline MADRS score measured weekly for 6 weeks post-treatment	—

Secondary

Measure	Time frame
Percentage reduction from baseline MADRS-score at 6 months follow-up., Clinical remission (defined as a MADRS-score of ≤8) and clinical response (defined as a reduction from baseline MADRS score of >50%) at 6 weeks follow-up., Percentage reduction from baseline GAD-7-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Percentage reduction from baseline PHQ-9-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Change in performance on the cognitive test battery at 1 week follow-up., Side effect questionnaire taken immediately after treatment., EQ5D questionnaire taken at 6 weeks follow-up.	—

Measure

Time frame

Percentage reduction from baseline MADRS-score at 6 months follow-up., Clinical remission (defined as a MADRS-score of ≤8) and clinical response (defined as a reduction from baseline MADRS score of >50%) at 6 weeks follow-up., Percentage reduction from baseline GAD-7-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Percentage reduction from baseline PHQ-9-score measured weekly for the first 6 weeks post-treatment and monthly for the remainder of 6 months., Change in performance on the cognitive test battery at 1 week follow-up., Side effect questionnaire taken immediately after treatment., EQ5D questionnaire taken at 6 weeks follow-up.

—

Countries

Netherlands

Outcome results

None listed